ELISA analyzers market seen reaching $1.01 billion by 2030

The global ELISA analyzers market is projected to rise from $0.75 billion in 2025 to $0.8 billion in 2026, with growth driven by infectious disease testing, automation, and demand for faster diagnostics. North America led in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - ELISA analyzers are becoming more important in clinical diagnostics as healthcare systems push for faster, more accurate testing. - The market’s growth reflects rising demand for automated tools that support infectious disease screening, lab efficiency, and point-of-care testing. - Wider adoption can affect how quickly labs diagnose infections and monitor disease spread.

What happened: - The Business Research Company released a 2026 market report on the enzyme-linked immunosorbent assay, or ELISA, analyzers market. - The report values the market at $0.75 billion in 2025 and projects growth to $0.8 billion in 2026. - The report forecasts the market will reach $1.01 billion by 2030. - The company says the market will grow at a 6.1% CAGR from 2025 to 2026 and a 6.0% CAGR through 2030.

The details: - Clinical diagnostic testing volumes, infectious disease screening, and broader adoption of automated laboratory instruments helped drive historical growth. - Demand for reliable immunoassays and standardized diagnostic protocols also supported market expansion. - Future growth is tied to investment in advanced diagnostic infrastructure, broader point-of-care testing, pharmaceutical and vaccine research, better lab efficiency, and demand for rapid assays. - ELISA analyzers detect and measure biological substances in samples using antibodies, antigens, and enzyme-linked reagents. - The instruments produce visible signals, often color changes, to indicate the amount of target analyte in a sample. - The technology improves diagnostic accuracy, consistency, processing speed, and reduces human error. - North America held the largest market share in 2025. - Asia-Pacific is expected to record the fastest growth during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa. - Emerging trends include fully automated ELISA workstations, high-throughput testing, chemiluminescence and fluorescence technologies, portable analyzers, and more automated lab workflows.

Between the lines: - The market outlook suggests laboratories are shifting toward systems that can handle more samples with less manual work. - The focus on portable and automated platforms points to more testing outside traditional central labs. - Rising infectious disease prevalence is a core demand driver, with the World Health Organization reporting in March 2025 that about 10.8 million people contracted tuberculosis in 2023.

What's next: - The market is likely to keep expanding as labs invest in faster, more automated diagnostic systems. - Growth opportunities appear strongest in Asia-Pacific and in technologies that improve speed, sensitivity, and throughput. - The report’s updated features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and key technology and future trend analysis. - Download a free sample of the report - View the full report

The bottom line: - ELISA analyzers are moving from a niche lab tool to a more central part of diagnostic testing, with automation and infectious disease screening driving the next stage of growth.